10x Genomics develops products that enhance genomic research, particularly in the life sciences sector. Their main offerings include tools for single-cell analysis, spatial gene expression, and immune profiling, which allow researchers to examine genetic information in detail. These products help scientists understand complex biological systems and are essential for personalized medicine and advanced research. 10x Genomics sells laboratory equipment, consumables like reagents and microfluidic chips, and software solutions for data analysis. Their focus on high-quality products and support distinguishes them from competitors, aiming to empower researchers in their quest to explore the human genome.

Venrock

Paladin Capital Group

Foresite Capital

Meritech Capital

Wells Fargo Capital Finance

Vision Fund

Fidelity Investments

Silicon Valley Bank

Verge Genomics

Sophia Genetics

Shivom

Biotechnology

Healthcare

10x Genomics

FY 2024 revenue of ~$611 million and Q4 2024 revenue of ~$165 million, representing 9% growth sequentiallyPLEASANTON, Calif., Jan. 12, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced preliminary, unaudited select results for the fourth quarter and full year ended December 31, 2024.Preliminary, Unaudited Select Fourth Quarter 2024 Financial ResultsRevenue of approximately $165.0 million for the three months ended December 31, 2024 , representing 9% growth sequentially and a 10% decrease as compared to the corresponding prior year period.for the three months ended , representing 9% growth sequentially and a 10% decrease as compared to the corresponding prior year period. Instruments revenue of approximately $24.4 million , representing 28% growth sequentially and a 37% decrease as compared to the corresponding prior year period. Instruments revenue consists of approximately $10.9 million of Chromium instruments revenue and $13.4 million of Spatial instruments revenue., representing 28% growth sequentially and a 37% decrease as compared to the corresponding prior year period. Instruments revenue consists of approximately of Chromium instruments revenue and of Spatial instruments revenue

10X Genomics Announces Preliminary Select Fourth Quarter And Full Year 2024 Results

PLEASANTON, Calif., Jan. 2, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, at 7:30 a.m. Pacific Time.Interested parties may access a live webcast of the fireside chat on the "Investors" section of the company's website at: https://investors.10xgenomics.com/. The webcast will be archived and available for replay for at least 30 days after the event.About 10x Genomics10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health

10X Genomics To Present At The 43Rd Annual J.P. Morgan Healthcare Conference

"Yesterday, the Court issued its ruling on the post-trial motions that followed the November 2023 jury verdict in the patent infringement case between NanoString and 10x Genomics.

Bruker 'respectfully disagrees' with District Court, to seek stay of injunction

PLEASANTON, Calif., Oct. 15, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the launch of two new Chromium products intended to democratize access to single cell analysis. The new offerings – GEM-X Flex and GEM-X Universal Multiplex – introduce significant improvements in performance, workflow and cost effectiveness, enabling more researchers to pursue single cell analysis for more applications.These launches are part of the company's strategy to drive widespread adoption of single cell analysis by lowering customer costs in multiple directions: per cell, per sample, per experiment and per project. With these advances, 10x Genomics is addressing the growing demand for high-throughput single cell applications and providing cost-effective offerings to help new researchers getting started in single cell and existing labs looking to scale up their research."These launches are an integral part of our ongoing push to democratize single cell analysis and make it more accessible and more affordable for more researchers than ever before," said Michael Schnall-Levin, Founding Scientist and Chief Technology Officer at 10x Genomics. "They add to a growing list of new single cell products, protocols and capabilities that make 2024 the most exciting year of Chromium innovation in the platform's history

10X Genomics Delivers 'Single Cell For A Single Cent' With New Chromium Launches

PLEASANTON, Calif., Oct. 9, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced preliminary select results for the third quarter ended September 30, 2024.Preliminary Select Third Quarter 2024 ResultsRevenue of approximately $151.7 million for the third quarter ended September 30, 2024 , representing an approximate 1% decrease from the corresponding prior year period.for the third quarter ended , representing an approximate 1% decrease from the corresponding prior year period. Preliminary revenue by source for the third quarter is expected to be as follows: Instruments revenue of approximately $19.1 million , representing a 46% decrease from the corresponding prior year period. Instruments revenue consists of approximately $7.6 million of Chromium instruments revenue and $11.4 million of Spatial instruments revenue. Consumables revenue of approximately $126.2 million , representing 10% growth over the corresponding prior year period

10X Genomics Announces Preliminary Select Third Quarter 2024 Results

To overcome this challenge, 10X Genomics introduced the On-Chip Multiplex (OCM) solution, enabling multiplexing directly on the chip and eliminating the need for complex sample preparation, thus reducing handling time.

GEM-X Universal OCM: Optimizing Cost and Improving Efficiency in Single-Cell Research

The decision came after 10X Genomics revealed plans at an industry event to introduce new Single Cell (SC) products in the fourth quarter.

10X Genomics hold rating reiterated by TD Cowen

PLEASANTON, Calif., Dec. 23, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today it had secured a permanent injunction in the U.S. District Court for the District of Delaware against the GeoMx products sold by Bruker Corporation (Nasdaq: BRKR), which acquired the product line from NanoString Technologies. To minimize the risk of disruption to ongoing research, 10x Genomics requested a carve-out for GeoMx users who installed an instrument prior to the trial in November 2023.The injunction, which the Court said it will enter in January 2025, is expected to prohibit Bruker from making, using, selling or offering to sell in the United States its GeoMx Digital Spatial Profiler and associated instruments, reagents and services for RNA and protein detection. At the request of 10x Genomics, the injunction will not block ongoing research by researchers who installed a GeoMx instrument prior to November 18, 2023

U.S. District Court Awards 10X Genomics Permanent Injunction In Patent Infringement Lawsuit Against Bruker Corporation'S Geomx Products

Artificial intelligence continues to push the boundaries of science and health exploration. From mapping proteins to neurological networks, these systems continue to make game-changing impacts on the sector. This month, a group of advantageous researchers from the Institute of Psychiatry, Psychology & Neuroscience took AI integration further. They released a study in which AI algorithms were used to predict the metabolic age of patients. Here's what you need to know.Chronological Clock vs Biological ClockTo grasp the importance of this development, it's vital to understand the differences between your chronological and biological age. These two methods of determining the age of your body are used in different ways by healthcare professionals

Can Ai Predict One’S Metabolomic Age And Tailor Health Plans Accordingly?

PLEASANTON, Calif., Jan. 2, 2025 /PRNewswire/ - 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, at 7:30 a.m. Pacific Time.

10x Genomics

Biotechnology tools for genomic research

10x Genomics

Biotechnology tools for genomic research

About

Simplify's Take

What believers are saying

What critics are saying

What makes 10x Genomics unique

6 month growth

1 year growth

2 year growth

Benefits

Recently Posted Jobs

10x Genomics is Hiring for 0 Jobs on Simplify!